NCT01919164 arm group 874b5e4f3b65cef0d7f2824a6171869a [clinicaltrials_resource:NCT01919164/arm-group/874b5e4f3b65cef0d7f2824a6171869a]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01919164 arm group 874b5e4f3b65cef0d7f2824a6171869a [clinicaltrials_resource:NCT01919164/arm-group/874b5e4f3b65cef0d7f2824a6171869a]
Bio2RDF identifier
NCT01919164/arm-group/874b5e4f3b65cef0d7f2824a6171869a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 4b5e4f3b65cef0d7f2824a6171869a
description [clinicaltrials_vocabulary:description]
AS902330, 100 mcg, will be adm ...... ks, with follow-up to 2 years.
identifier
clinicaltrials_resource:NCT01919164/arm-group/874b5e4f3b65cef0d7f2824a6171869a
title
NCT01919164 arm group 874b5e4f3b65cef0d7f2824a6171869a
@en
type
label
NCT01919164 arm group 874b5e4f ...... b5e4f3b65cef0d7f2824a6171869a]
@en